These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19187516)

  • 41. Global review of health care surveys using lot quality assurance sampling (LQAS), 1984-2004.
    Robertson SE; Valadez JJ
    Soc Sci Med; 2006 Sep; 63(6):1648-60. PubMed ID: 16764978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estimation after classification using lot quality assurance sampling: corrections for curtailed sampling with application to evaluating polio vaccination campaigns.
    Olives C; Valadez JJ; Pagano M
    Trop Med Int Health; 2014 Mar; 19(3):321-330. PubMed ID: 24382319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Estimation of measles vaccination coverage using the Lot Quality Assurance Sampling (LQAS) method--Tamilnadu, India, 2002-2003.
    Sivasankaran S; Manickam P; Ramakrishnan R; Hutin Y; Gupte MD;
    MMWR Suppl; 2006 Apr; 55(1):16-9. PubMed ID: 16645577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccination coverage in the context of the emerging Yellow Fever threat in French Guiana.
    Flamand C; Bailly S; Fritzell C; Fernandes Pellerin S; Toure A; Chateau N; Saout M; Linares S; Dubois F; Filleul L; Kazanji M
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007661. PubMed ID: 31425507
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Late vaccination reinforcement during a measles epidemic in Niamey, Niger (2003-2004).
    Dubray C; Gervelmeyer A; Djibo A; Jeanne I; Fermon F; Soulier MH; Grais RF; Guerin PJ
    Vaccine; 2006 May; 24(18):3984-9. PubMed ID: 16540214
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Yellow fever vaccination: update on rare and severe adverse effects].
    Receveur MC; Bruyand M; Pistone T; Malvy D
    Med Mal Infect; 2009 Apr; 39(4):234-41. PubMed ID: 19167852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Methods for estimating population coverage of mass distribution programmes: a review of practices in relation to trachoma control.
    Cromwell EA; Ngondi J; McFarland D; King JD; Emerson PM
    Trans R Soc Trop Med Hyg; 2012 Oct; 106(10):588-95. PubMed ID: 22884927
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Linking yellow fever vaccinator approval and renewal with training in travel medicine in New Zealand.
    O'Brien B; Leggat PA
    Travel Med Infect Dis; 2010 Jul; 8(4):210-2. PubMed ID: 20970723
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lot quality assurance sampling to assess coverage and compliance following mass drug administration to eliminate lymphatic filariasis in Fiji: A methodological approach.
    Rinamalo M; Pezzoli L; Kama M; Rafai E; Kubuabola I; Salusalu M; Kim SH
    PLoS One; 2020; 15(9):e0238622. PubMed ID: 32946536
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Eliminating yellow fever epidemics in Africa: Vaccine demand forecast and impact modelling.
    Jean K; Hamlet A; Benzler J; Cibrelus L; Gaythorpe KAM; Sall A; Ferguson NM; Garske T
    PLoS Negl Trop Dis; 2020 May; 14(5):e0008304. PubMed ID: 32379756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Yellow fever vaccination: some thoughts on how much is enough [Vaccine 23 (2005) 3908-3914].
    Martins RM; Galler R; Freire MS; Camacho LA; de Lourdes S Maia M; Homma A
    Vaccine; 2007 Jan; 25(1):10-1. PubMed ID: 16448728
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vaccine administration decision making: the case of yellow fever vaccine.
    Lown BA; Chen LH; Wilson ME; Sisson E; Gershman M; Yanni E; Jentes ES; Hochberg NS; Hamer DH; Barnett ED
    Clin Infect Dis; 2012 Sep; 55(6):837-43. PubMed ID: 22670048
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Integrated approach to yellow fever surveillance: pilot study in Senegal in 2003-2004].
    Faye O; Diallo M; Dia I; Ba Y; Faye O; Mondo M; Sylla R; Faye PC; Sall AA
    Bull Soc Pathol Exot; 2007 Aug; 100(3):187-92. PubMed ID: 17824313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Modern features of epidemiology and prophylaxis of yellow fever].
    Liashenko NI; Lukin EP
    Voen Med Zh; 2010 Jun; 331(6):32-6. PubMed ID: 20731094
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Belgian traveler who acquired yellow fever in the Gambia.
    Colebunders R; Mariage JL; Coche JC; Pirenne B; Kempinaire S; Hantson P; Van Gompel A; Niedrig M; Van Esbroeck M; Bailey R; Drosten C; Schmitz H
    Clin Infect Dis; 2002 Nov; 35(10):e113-6. PubMed ID: 12410495
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EPI vaccination in Nepal.
    Jha N; Kannan AT; Paudel IS; Niraula S
    Southeast Asian J Trop Med Public Health; 2001 Sep; 32(3):547-52. PubMed ID: 11944715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparing two survey methods of measuring health-related indicators: Lot Quality Assurance Sampling and Demographic Health Surveys.
    Anoke SC; Mwai P; Jeffery C; Valadez JJ; Pagano M
    Trop Med Int Health; 2015 Dec; 20(12):1756-70. PubMed ID: 26425920
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lot quality assurance sampling for monitoring immunization programmes: cost-efficient or quick and dirty?
    Sandiford P
    Health Policy Plan; 1993 Sep; 8(3):217-23. PubMed ID: 10128376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A field test of three LQAS designs to assess the prevalence of acute malnutrition.
    Deitchler M; Valadez JJ; Egge K; Fernandez S; Hennigan M
    Int J Epidemiol; 2007 Aug; 36(4):858-64. PubMed ID: 17517808
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of a lot quality assurance sampling methodology to assess and manage primary health interventions in conflict-affected West Darfur, Sudan.
    Pham K; Sharpe EC; Weiss WM; Vu A
    Popul Health Metr; 2016; 14():34. PubMed ID: 27757070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.